Introduction: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process as well as to hypothesize future researcher purposes. Areas covered: A literature search was conducted using keywords apt to identify information on safety profile of the fluoroquinolones. Publications concerned with descriptive and etiological surveys were manually reviewed. Expert opinion: Cardiac alterations and blood glucose impairments might be associated with any fluoroquinolone. However, the benefit/risk profile of these agents could be stratified for the single compounds. Several predisposing factors, such as diabetes, heart illnesses and their related pharmacotherapies, might exacerbate the risk of potentially serious adverse events. In this context, the opportunity of the more appropriate choice among different fluoroquinolones could be applicable.

Pugi, A., Longo, L., Bartoloni, A., Rossolini, G.M., Mugelli, A., Vannacci, A., et al. (2012). Cardiovascular and metabolic safety profiles of the fluoroquinolones. EXPERT OPINION ON DRUG SAFETY, 11(1), 53-69 [10.1517/14740338.2011.624512].

Cardiovascular and metabolic safety profiles of the fluoroquinolones

ROSSOLINI G. M.;
2012-01-01

Abstract

Introduction: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process as well as to hypothesize future researcher purposes. Areas covered: A literature search was conducted using keywords apt to identify information on safety profile of the fluoroquinolones. Publications concerned with descriptive and etiological surveys were manually reviewed. Expert opinion: Cardiac alterations and blood glucose impairments might be associated with any fluoroquinolone. However, the benefit/risk profile of these agents could be stratified for the single compounds. Several predisposing factors, such as diabetes, heart illnesses and their related pharmacotherapies, might exacerbate the risk of potentially serious adverse events. In this context, the opportunity of the more appropriate choice among different fluoroquinolones could be applicable.
2012
Pugi, A., Longo, L., Bartoloni, A., Rossolini, G.M., Mugelli, A., Vannacci, A., et al. (2012). Cardiovascular and metabolic safety profiles of the fluoroquinolones. EXPERT OPINION ON DRUG SAFETY, 11(1), 53-69 [10.1517/14740338.2011.624512].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/20126
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo